7-benzyl-1,3-dioxo-1,2,3,4,5,6,7,8-octahydro-[2,7]-naphthyridine-4-carbonitrile | 1228692-26-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 7-benzyl-1,3-dioxo-1,2,3,4,5,6,7,8-octahydro-[2,7]-naphthyridine-4-carbonitrile
• 英文别名: 7-Benzyl-1,3-dioxo-4,5,6,8-tetrahydro-2,7-naphthyridine-4-carbonitrile；7-benzyl-1,3-dioxo-4,5,6,8-tetrahydro-2,7-naphthyridine-4-carbonitrile
• CAS: 1228692-26-9
• 化学式: C₁₆H₁₅N₃O₂
• 分子量: 281.314
• InChiKey: QMWMORFWGNOTGT-UHFFFAOYSA-N

物化性质

• 熔点：
  258-260 °C
• 沸点：
  549.2±50.0 °C(Predicted)
• 密度：
  1.32±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  73.2
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  7-benzyl-1,3-dioxo-1,2,3,4,5,6,7,8-octahydro-[2,7]-naphthyridine-4-carbonitrile 在 palladium 10% on activated carbon 、 氢气 、 三乙胺 、 三氯氧磷 作用下， 以 甲醇 为溶剂， 反应 7.0h， 生成 7-benzyl-5,6,7,8-tetrahydro-[2,7]-naphthyridine-4-carbonitrile
  参考文献：
  名称：

  KINASE INHIBITORS

  摘要：

  本发明涉及以下式I和II的化合物 其中变量如本文所定义。这些化合物能够调节酪氨酸激酶信号传导，以调节、调控和/或抑制异常细胞增殖。

  公开号：

  US20130237538A1
• 作为产物：
  描述：

  1-苄基-3-乙氧羰基-4-哌啶酮盐酸盐 在 碳酸氢钠 、 potassium hydroxide 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 5.0h， 生成 7-benzyl-1,3-dioxo-1,2,3,4,5,6,7,8-octahydro-[2,7]-naphthyridine-4-carbonitrile
  参考文献：
  名称：

  KINASE INHIBITORS

  摘要：

  本发明涉及以下式I和II的化合物 其中变量如本文所定义。这些化合物能够调节酪氨酸激酶信号传导，以调节、调控和/或抑制异常细胞增殖。

  公开号：

  US20130237538A1

文献信息

• METHOD OF TREATING CONDITIIONS WITH KINASE INHIBITORS
  申请人：ALLERGAN, INC.

  公开号：US20130237537A1

  公开（公告）日：2013-09-12

  The present invention relates to a method of treating ophthalmic diseases and conditions, e.g. diabetic retinopathy, age-related macular degeneration, retinopathy of prematurity, etc., in a subject comprising administering to said subject a therapeutically effective amount of at least one compound of formula I or a prodrug, pharmaceutically acceptable salt, racemic mixtures or enantiomers of said compound. The compounds of formula I are capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.

  本发明涉及一种治疗眼科疾病和病况的方法，例如糖尿病视网膜病变、老年性黄斑变性、早产儿视网膜病变等，在一个受试者中，包括向该受试者施用至少一种式I的化合物的治疗有效量，或者该化合物的前药、药学上可接受的盐、拉丁混合物或对映体。式I的化合物能够调节酪氨酸激酶信号传导，以调节、调制和/或抑制异常细胞增殖。
• Synthesis of 7-benzyl-5-(piperidin-1-yl)-6,7,8,9-tetrahydro-3H-pyrazolo[3,4-c][2,7]naphthyridin-1-ylamine and its analogs as bombesin receptor subtype-3 agonists
  作者：Cheng Guo、Peter R. Guzzo、Mark Hadden、Bruce J. Sargent、Larry Yet、Yanqing Kan、Oksana Palyha、Theresa M. Kelly、Xiaoming Guan、Kim Rosko、Karen Gagen、Joseph M. Metzger、Jasminka Dragovic、Kathryn Lyons、Linus S. Lin、Ravi P. Nargund

  DOI：10.1016/j.bmcl.2010.03.065

  日期：2010.5

  The original structure of a high-throughput screening hit obtained from an external vendor was revised based on multiple NMR studies. The active compound was re-synthesized via a novel route and its structure and biological activity as a BRS-3 agonist were unambiguously confirmed. Multi-gram quantities of the hit were prepared for pharmacokinetic and efficacy studies. The synthetic strategy allowed for the preparation of multiple analogs for SAR exploration. (C) 2010 Elsevier Ltd. All rights reserved.
• METHOD OF TREATING OPHTHALMIC CONDITIONS WITH KINASE INHIBITORS
  申请人：ALLERGAN, INC.

  公开号：EP2825166A1

  公开（公告）日：2015-01-21
• DIHYDROPYRIDOPYRIMIDINE AND DIHYDRONAPHTHYRIDINE DERIVATIVES AS TYROSINE KINASE INHIBITORS OF ESPECIALLY VEGF AND PDGF
  申请人：ALLERGAN, INC.

  公开号：EP2825537A1

  公开（公告）日：2015-01-21
• METHOD OF TREATING CONDITIONS WITH KINASE INHIBITORS
  申请人：Allergan, Inc.

  公开号：US20170143728A1

  公开（公告）日：2017-05-25

  The present invention relates to a method of treating ophthalmic diseases and conditions, e.g. diabetic retinopathy, age-related macular degeneration, retinopathy of prematurity, etc., in a subject comprising administering to said subject a therapeutically effective amount of at least one compound of formula I or a prodrug, pharmaceutically acceptable salt, racemic mixtures or enantiomers of said compound. The compounds of formula I are capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.